Bálint Nagy

Prof. Bálint Nagy

University of Debrecen, Faculty of Medicine, Department of Humangenetics
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2021 in Biomedical Journal
Verified
Journal Article
Open access
OPOndrej Pös
Ondrej Pös
JRJan Radvanszky
Jan Radvanszky
GBGergely Buglyó
Gergely Buglyó
ZPZuzana Pös
Zuzana Pös
DRDiana Rusnakova
Diana Rusnakova
TSTomas Szemes
Tomas Szemes
Copy number variants (CNVs) were the subject of extensive research in the past years. They are common features of the human genome that play an important role in evolution, contribute to population diversity, development of certain diseases, and influence host–microbiome interactions. CNVs have found application in the molecular diagnosis of many diseases and in non-invasive prenatal care, but their full potential is only emerging. CNVs are expected to have a tremendous impact on screening, diagnosis, prognosis, and monitoring of several disorders, including cancer and cardiovascular disease. Here, we comprehensively review basic definitions of the term CNV, outline mechanisms and factors involved in CNV formation, and discuss their evolutionary and pathological aspects. We suggest a need for better defined distinguishing criteria and boundaries between known types of CNVs.

23 April 2018 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
OPOndrej Pös
Ondrej Pös
OBOrsolya Biró
Orsolya Biró
TSTomas Szemes
Tomas Szemes
Bálint NagyBálint Nagy
Bálint Nagy

Verified
Journal Article
Open access
PDF file
MSMelinda Szilágyi-Bónizs
Melinda Szilágyi-Bónizs
OPOndrej Pös
Ondrej Pös
ÉMÉva Márton
Éva Márton
GBGergely Buglyó
Gergely Buglyó
BSBeata Soltesz
Beata Soltesz
Bálint NagyBálint Nagy
Bálint Nagy
Liquid biopsy recently became a very promising diagnostic method that has several advantages over conventional invasive methods. Liquid biopsy may serve as a source of several important biomarkers including cell-free nucleic acids (cf-NAs). Cf-DNA is widely used in prenatal testing in order to characterize fetal genetic disorders. Analysis of cf-DNA may provide information about the mutation profile of tumor cells, while cell-free non-coding RNAs are promising biomarker candidates in the diagnosis and prognosis of cancer. Many of these markers have the potential to help clinicians in therapy selection and in the follow-up of patients. Thus, cf-NA-based diagnostics represent a new path in personalized medicine. Although several reviews are available in the field, most of them focus on a limited number of cf-NA types. In this review, we give an overview about all known cf-NAs including cf-DNA, cf-mtDNA and cell-free non-coding RNA (miRNA, lncRNA, circRNA, piRNA, YRNA, and vtRNA) by discussing their biogenesis, biological function and potential as biomarker candidates in liquid biopsy. We also outline possible future directions in the field.

1 June 2019 in Journal of Biotechnology
Verified
Journal Article
Closed access
JKJudit Szilvia Keserű
Judit Szilvia Keserű
BSBeáta Soltész
Beáta Soltész
JLJános Lukács
János Lukács
ÉMÉva Márton
Éva Márton
MSMelinda Szilágyi-Bónizs
Melinda Szilágyi-Bónizs
Bálint NagyBálint Nagy
Bálint Nagy

Verified
Journal Article
Open access
PDF file
ZBZsuzsanna Birkó
Zsuzsanna Birkó
Bálint NagyBálint Nagy
Bálint Nagy
ÁKÁlmos Klekner
Álmos Klekner
JVJózsef Virga
József Virga
Glioblastoma is a primary Central Nervous System (CNS) malignancy with poor survival. Treatment options are scarce and despite the extremely heterogeneous nature of the disease, clinicians lack prognostic and predictive markers to characterize patients with different outcomes. Certain immunohistochemistry, FISH, or PCR-based molecular markers, including isocitrate dehydrogenase1/2 (IDH1/2) mutations, epidermal growth factor receptor variant III (EGFRvIII) mutation, vascular endothelial growth factor overexpression (VEGF) overexpression, or (O6-Methylguanine-DNA methyltransferase promoter) MGMT promoter methylation status, are well-described; however, their clinical usefulness and accuracy is limited, and tumor tissue samples are always necessary. Liquid biopsy is a developing field of diagnostics and patient follow up in multiple types of cancer. Fragments of circulating nucleic acids are collected in various forms from different bodily fluids, including serum, urine, or cerebrospinal fluid in order to measure the quality and quantity of these markers. Multiple types of nucleic acids can be analyzed using liquid biopsy. Circulating cell-free DNA, mitochondrial DNA, or the more stable long and small non-coding RNAs, circular RNAs, or microRNAs can be identified and measured by novel PCR and next-generation sequencing-based methods. These markers can be used to detect the previously described alterations in a minimally invasive method. These markers can be used to differentiate patients with poor or better prognosis, or to identify patients who do not respond to therapy. Liquid biopsy can be used to detect recurrent disease, often earlier than using imaging modalities. Liquid biopsy is a rapidly developing field, and similarly to other types of cancer, measuring circulating tumor-derived nucleic acids from biological fluid samples could be the future of differential diagnostics, patient stratification, and follow up in the future in glioblastoma as well.

16 January 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
OPOndrej Pös
Ondrej Pös
JRJan Radvanszky
Jan Radvanszky
JSJakub Styk
Jakub Styk
ZPZuzana Pös
Zuzana Pös
GBGergely Buglyó
Gergely Buglyó
TSTomas Szemes
Tomas Szemes
Gains and losses of large segments of genomic DNA, known as copy number variants (CNVs) gained considerable interest in clinical diagnostics lately, as particular forms may lead to inherited genetic diseases. In recent decades, researchers developed a wide variety of cytogenetic and molecular methods with different detection capabilities to detect clinically relevant CNVs. In this review, we summarize methodological progress from conventional approaches to current state of the art techniques capable of detecting CNVs from a few bases up to several megabases. Although the recent rapid progress of sequencing methods has enabled precise detection of CNVs, determining their functional effect on cellular and whole-body physiology remains a challenge. Here, we provide a comprehensive list of databases and bioinformatics tools that may serve as useful assets for researchers, laboratory diagnosticians, and clinical geneticists facing the challenge of CNV detection and interpretation.